These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Pegaptanib sodium in treatment of choroidal neovascularization secondary to age-related macular degeneration. One year results].
    Author: Wykrota H, Gajdzik-Gajdecka U, Trzciakowski K, Smuzyńska M.
    Journal: Klin Oczna; 2007; 109(10-12):394-401. PubMed ID: 18488381.
    Abstract:
    PURPOSE: Prospective, noncomparative (nonrandomized, uncontrolled), consecutive interventional case series study--to evaluate the efficacy of intravitreal pegaptanib sodium in the treatment of choroidal neovascularization due to age-related macular degeneration in treatment-naive patients. MATERIAL AND METHODS: 38 eyes of 38 patients were treated with intravitreal pegaptanib. All angiographic subtypes of lesions were qualified to the treatment. Intravitreal injections were performed every 6 weeks at the discretion of the treating ophthalmologist. Retreatment criteria were based on evaluation of presence of submacular fluid and/or increase in macular thickness seen in OCT, new retinal hemorrhage, and loss of visual acuity (VA). RESULTS: The VA outcomes were assessed at 48-th week of the study. The mean change in VA for all lesions was a loss of 9.4 ETDRS letters. Percent of patients losing less than 15 ETDRS letters in predominantly classic subgroup was 68%, minimally classic--65% and pure occult--72%. 7% of patients gained more than 1 ETDRS lines of VA whereas 2% more than 3 ETDRS lines. 8.5% of patients lost 30 and more ETDRS letters at 48-th week of the study. Results were better for smaller (<4 DA) lesions, eyes with better (> 54 ETDRS letters) baseline VA and for pure occult lesions. CONCLUSIONS: Pegaptanib sodium effectively preserve vision in approximately 70% of patients with wet AMD in 1-year period of observation. Eyes with more advanced lesions seen at baseline have an increased risk of worse VA outcomes.
    [Abstract] [Full Text] [Related] [New Search]